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Background
To investigate the incidence of local reactions and
systemic reactions of subcutaneous immunotherapy in
an Allergy Center in Monterrey, Nuevo León, México.
Methods
We conducted a retrospective chart review of patients
receiving subcutaneous immunotherapy in our allergy
practice between November 2012 to June 2013 looking
at the incidence of local and systemic allergic reactions.
Results
A total of 8069 subcutaneous immunotherapy injections
were applied between November 2012 to June 2013.
Among them, 1071 local reactions (LR) were observed
(13.2%). Of the total of LR, 1067 were considered small
local reactions (Local reaction no larger than the size of
the palm of the patient’s hand [<80 – 100mm]) (99.6%)
and 4 were considered large local reactions (large local
reaction larger than the size of the patient’s palm [> 80–
100 mm]) (0.4%). 32 systemic reactions (0.4%) were
observed. These SR included respiratory symptoms and
cutaneous symptoms. We used the World Allergy Organi-
zation Subcutaneous Immunotherapy Systemic Reaction
Grading System to classify the SR. 27 SR were classified as
grade 1 (84.3%). 3 SR were classified as grade 2 (9.3%),
characterized by respiratory symptoms (cough, wheezing)
and responded to an inhaled bronchodilator. 2 SR were
classified as grade 3 (6.4%) characterized by respiratory
symptoms (cough, wheezing, shortness of breath) and did
not respond to inhaled bronchodilator and required
epinephrine treatment (0.02% of total injections). Neither
grade IV nor V systemic reactions were observed.
Conclusions
The prevalence of adverse reactions to subcutaneous
immunotherapy observed in our study is similar to the
reported worldwide. The most reactions are local, small
and self limited. The low prevalence of systemic reac-
tions and the absence of fatalities makes subcutaneous
immunotherapy a safe therapy.
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